Publication:
Characterization and vaccine potential of Fasciola gigantica saposin-like protein 1 (SAP-1)

dc.contributor.authorPornanan Kueakhaien_US
dc.contributor.authorNarin Changklungmoaen_US
dc.contributor.authorPinkamon Waseewiwaten_US
dc.contributor.authorThanaporn Thanasinpaiboonen_US
dc.contributor.authorWerachon Cheukamuden_US
dc.contributor.authorPannigan Chaichanasaken_US
dc.contributor.authorPrasert Sobhonen_US
dc.contributor.otherBurapha Universityen_US
dc.contributor.otherMahanakorn University of Technologyen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-12-21T08:03:00Z
dc.date.accessioned2019-03-14T08:03:53Z
dc.date.available2018-12-21T08:03:00Z
dc.date.available2019-03-14T08:03:53Z
dc.date.issued2017-01-15en_US
dc.description.abstract© 2016 Elsevier B.V. The recombinant Fasciola gigantica Saposin-like protien-1 (rFgSAP-1) was cloned by polymerase chain reaction (PCR) from NEJ cDNA, expressed in Escherichia coli BL21 (DE3) and used for production of a polyclonal antibody in rabbits (anti-rFgSAP-1). By immunoblotting and immunohistochemistry, rabbit IgG anti-rFgSAP-1 reacted with rFgSAP-1 at a molecular weight 12 kDa, but not with rFgSAP-2. The rFgSAP-1 reacted with antisera from mouse infected with F. gigantica metacercariae collected at 2, 4, and 6 weeks after infection. The FgSAP-1 protein was expressed at a high level in the caecal epithelium of metacercariae and NEJs. The vaccination was performed in Imprinting Control Region (ICR) mice (n = 10) by subcutaneous injection with 50 μg of rFgSAP-1 combined with Alum adjuvant. Two weeks after the second boost, mice were infected with 15 metacercariae per mouse by the oral route. The percents protection of rFgSAP-1 vaccine were estimated to be 73.2% and 74.3% when compared with non vaccinated-infected and adjuvant-infected controls, respectively. The levels of IgG1 and IgG2a specific to rFgSAP-1 in the immune sera, which are indicative of Th2 and Th1 immune responses, were inversely and significantly correlated with the numbers of worm recoveries. The rFgSAP-1-vaccinated mice showed significantly reduced levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and liver damage. These indicated that rFgSAP-1 has strong potential as a vaccine candidate against F. gigantica, whose efficacy will be studied further in large economic animals including cattle, sheep, and goat.en_US
dc.identifier.citationVeterinary Parasitology. Vol.233, (2017), 115-122en_US
dc.identifier.doi10.1016/j.vetpar.2016.12.009en_US
dc.identifier.issn18732550en_US
dc.identifier.issn03044017en_US
dc.identifier.other2-s2.0-85006726069en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/42856
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85006726069&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.titleCharacterization and vaccine potential of Fasciola gigantica saposin-like protein 1 (SAP-1)en_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85006726069&origin=inwarden_US

Files

Collections